SCHEMBL2236294

SCHEMBL2236294

COC(=O)NN(C(=O)Oc1ccc(Cl)cc1)c1ccccc1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.47
CYP11B1 P15538 2/20 0.46
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
LMNA P02545 4/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 2/20 0.40
LIPE Q05469 1/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PNLIP P16233 1/20 0.38
CYP11B2 P19099 1/20 0.38
HPGD P15428 3/20 0.38
TAAR1 Q96RJ0 1/20 0.38
XBP1 P17861 1/20 0.38
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2235392 0.90 POLB (0.41) ATMMEN1KMT2AL3MBTL1ALDH1A1
SCHEMBL2232497 0.89 MAPT (0.41) ATMMEN1KMT2ALMNAPOLB
SCHEMBL2232860 0.85 ATM (0.44) ATMKMT2AL3MBTL1ALDH1A1POLB
SCHEMBL2233414 0.84 LIPE (0.53) CYP11B1MEN1KMT2ALIPENPSR1
SCHEMBL2233290 0.83 ALDH1A1 (0.50) ATMMEN1KMT2ALMNAALDH1A1
SCHEMBL2234676 0.82 L3MBTL1 (0.54) ATMMEN1KMT2ALMNAL3MBTL1
SCHEMBL2235417 0.81 KMT2A (0.43) MEN1KMT2AL3MBTL1ALDH1A1SMN1; SMN2
SCHEMBL2234591 0.79 L3MBTL1 (0.48) ATMMEN1KMT2ALMNAL3MBTL1
SCHEMBL2237995 0.79 HPGD (0.41) MEN1KMT2ALMNAALDH1A1POLB
SCHEMBL11620797 0.78 STAT3 (0.43) ATMMEN1KMT2AL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299264-B2 Method for producing oxadiazolinone compound and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-30 US disclosed
US-20110207936-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-25 US disclosed
EP-2357167-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF Sumitomo Chemical Company, Limited (JP) 2011-08-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207936-A1 METHOD FOR PRODUCING OXADIAZOLINONE COMPOUND AND INTERMEDIATE THEREOF AHR, CYP1B1, AR ATM 540/4885CYP11B1 6/4885MEN1 2516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.